Introduction. The aim of this study was to assess the impact of tamponade when uterotonic agents fail, on the need for surgery or interventional radiology. Material and methods. All women who received sulprostone for postpartum hemorrhage were retrospectively compared over two periods [December 2008 to December 2010 without use of tamponade (period 1) and June 2011 to June 2013 with use of tamponade (period 2)] in the case of sulprostone failure (STROBE compliant retrospective cohort study). During period 2, interventional radiology or surgery was used only in the case of tamponade failure. Results. 165 women were included (74 for period 1, 91 for period 2). The rate of interventional radiology or surgery significantly decreased from period 1 (21 of 74 women, 28.4%) to period 2 (six of 91 women, 6.6%, p = 0.0003). The rate of assumed failure of uterotonic agents was higher for period 2: 22 of 74 women (29.7%) during period 1, and 41 of 91 (45.1%, p = 0.0439) during period 2. The success rate of tamponade was 92.1% (35 of 38 women). Conclusions. Although the efficacy of tamponade should be viewed in the light of its widespread use, our findings confirm that tamponade significantly reduces the need for interventional radiology or surgery for postpartum hemorrhage treatment.
Introduction
Postpartum hemorrhage (PPH), defined by blood loss of 500 mL or more in the 24 h following childbirth, occurs in 5% of deliveries and is severe [blood loss of ≥1000 mL (1)] in 1.3% of cases (2) . In severe or persistent PPH, the French National College of Obstetricians and Gynecologists (CNGOF) recommends the use of sulprostone after failure
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of oxytocin and other initial measures, and tamponade in the case of failure of sulprostone (3, 4) . The World Health Organization and the American Congress of Obstetricians and Gynecologists consider that uterine tamponade can be used in cases of uterine atony after failure of uterotonic agents (1, 5) . If uterotonic agents, with or without tamponade, fail, embolization or surgery is recommended (1, 2, 5) .
Uterine tamponade uses dedicated balloons (6) , the aim being to apply internal pressure in the case of uterine atony, with a threefold effect: compression of the placental bed, uterine contraction, and reduction in uterine blood flow (7, 8) .
The efficacy of balloon tamponade, defined by the absence of a need for more invasive procedures (4), i.e. embolization or surgery, is between 44 and 98% (6, 7, (9) (10) (11) (12) (13) (14) (15) (16) . Surgical methods in the treatment of PPH are vascular ligation, uterine compression sutures and hysterectomy. Uterine tamponade is considered less invasive than embolization or surgery. There is only one previous retrospective study evaluating the efficacy of second-line treatments (tamponade, interventional radiology, and surgery) after failure of uterotonic agents over two comparative periods (17) . The subjective nature of the criterion "failure of uterotonic agents" is one of the main potential biases of all the available studies evaluating the efficacy of the tamponade method. Indeed, tamponade being much simpler to implement than embolization and surgery, it is likely that balloons are regularly used in women who are still bleeding moderately despite administration of uterotonic agents, but who would not need additional care other than continuing medical treatment. The effectiveness of tamponade is therefore potentially overestimated. The aim of this study was to assess the impact of tamponade, when uterotonic agents fail, on the need for surgery or interventional radiology. Given the subjective nature of the criterion "failure of uterotonic agents," treatments (i.e. tamponade, embolization or surgery) were compared in all women who received sulprostone, over two periods (with or without tamponade use).
Material and methods
Two-year periods were studied retrospectively: December 2008 to December 2010 without use of tamponade (period 1) and June 2011 to June 2013 with use of tamponade (period 2). The two study periods were deliberately separated by six months, corresponding to the period during which we familiarized ourselves with balloon tamponade. During this learning period, balloon tamponade was used occasionally and was not part of our treatment protocols. All women treated with sulprostone for PPH during the two periods in the obstetrics unit of the academic hospital of Lorraine, France, were included.
In the first period, our protocol for management of PPH followed the 2004 CNGOF recommendations. Initial management consisted of urinary catheterization, examination of the uterine cavity, uterine massage, oxytocin and examination of the birth canal. If bleeding persisted after 15-30 min, intravenous sulprostone (Nalador â , Bayer Healthcare SAS, Loos, France) was administered using an electric syringe pump. If bleeding persisted despite sulprostone treatment, surgical management (vascular ligation, uterine compression sutures, and hysterectomy as a last resort) or uterine artery embolization by interventional radiology was then performed (3).
In the second period, balloon tamponade was used routinely after sulprostone treatment failure following vaginal delivery. The criterion for changing to the next treatment was the persistence of bleeding. In the case of severe PPH, the time to implementation of second-line therapy never exceeded 30 min, and could be shortened in the case of poor maternal hemodynamic status. When blood loss was between 500 and 1000 mL, the time to implementation of second-line therapy was up to one hour. The Bakri Postpartum Balloon â (Cook Medical INC., Bloomington, IN, USA) was available in our department. It was progressively instilled with saline until bleeding stopped (tamponade test), with an authorized maximum of 500 mL (6) . In the case of cesarean section, balloon tamponade was possible but not obligatory and was left to the discretion of the obstetrician. The level of evidence regarding the efficacy and safety of tamponade after cesarean section was very poor at the beginning of period 2 (and still is), so it was not possible to recommend its specific use. Failure of balloon tamponade was defined by persistence of bleeding requiring surgery or interventional radiology (3).
The medical records of all women treated with sulprostone for PPH during the two study periods were identified in our database. Anonymous data processing was used once the women agreed to participate in the study. The study was approved by the French ethics committee for research in obstetrics and gynecology (IRB number: CEROG OBS 2015-06-06).
Maternal characteristics (age, parity, history of PPH, scarred uterus) were compared in the two study periods, as were pregnancy (gestational age and PPH risk factors), labor and delivery (spontaneous or induced labor, duration of labor, mode of delivery, type of placenta removal, birthweight, initial management of PPH, causes of PPH, estimated blood loss).
The main endpoint in the case of failure of sulprostone was the rate of uterine artery embolization or surgery (vascular ligation, uterine compression sutures, hysterectomy). This rate and the rate of estimated failure of uterotonic agents (i.e. sulprostone) were compared for the two periods. Sulprostone was deemed to have failed whenever tamponade, embolization or surgery was used. The number of repeat surgical interventions, the rate of transfusion, the postpartum hemoglobin level, the length of hospital stay, and the short-term rate of maternal complications (defined as any complication occurring after PPH resolution and during hospital stay) were also compared between the two periods.
Statistical analysis was performed using R-project software, version 2.11.1 (R Development Core Team, http:// www.R-project.org). Student's t-test was used for comparison of quantitative variables. For qualitative variables, distribution among the groups was compared using the Chi-square test, except when any data point included had an expected frequency of less than 5, in which case Fisher's exact test was used. A p-value of less than 0.05 was considered to be statistically significant.
Results
Of the 7207 women who gave birth in our unit between December 2008 and December 2010 (period 1), 74 (1.03%) received sulprostone for the treatment of PPH. Of the 6652 women who gave birth in our unit between June 2011 and June 2013 (period 2), 91 (1.37%) received sulprostone (p = 0.0643) (Figure 1 ). These 165 women (74 in period 1 and 91 in period 2) included in the study were comparable in terms of maternal age, parity, PPH risk factors, gestational age, mode of delivery, duration of labor, birthweight, and rate of transfer from another unit for PPH management ( Table 1) .
The primary causes of PPH were similar in the two periods (Table 2) , with uterine atony predominating (91.9% for period 1 and 96.7% for period 2, p = 0.244). The remaining patients may have had another primary cause of PPH (Table 2 ) and some may have had multiple causes of PPH. Atony was the only cause of PPH in 43 (58.1%) women during period 1 and 57 (62.6%) in period 2. All patients included presented atony, which appeared secondarily in few cases (8.1% in period 1, and 3.3% in period 2). Disseminated intravascular coagulation occurred in two (2.7%) women during period 1 and in three (3.3%) during period 2, and was in all these cases a complication of PPH.
Initial management of PPH did not differ significantly between the two periods in terms of examination of the uterine cavity, examination of the birth canal, urinary catheterization, uterine massage, use and dose of oxytocin. Estimated mean blood loss was 1234 mL (range: 200-5000 mL) in period 1 and 1157 mL (range: 400-3500 mL) in period 2 (p = 0.51). The percentage of severe PPH was 48% in period 1 and 61% in period 2. There was a significant increase in the rate of assumed failure of uterotonic agents in period 2 ( Table 3) : 22 of 74 women (29.7%) during period 1 vs. 41 of 91 women (45.1%) during period 2 (p = 0.0439). During the first period, treatments applied in cases of assumed failure of sulprostone were exclusively interventional radiology or surgery: 100% (22/22 women). During the second period, treatments were mainly less invasive (tamponade): 92.6% (38/41 women). Three women had more invasive procedures with no attempt at tamponade (3/41, 7.3%). In three cases the obstetrician chose not to insert the balloon during cesarean section; instead, vascular ligation was performed in two cases and uterine compression sutures in one. The percentage of women treated with embolization or surgical procedures decreased significantly between period 1 (21 of 74 women, 28.4%) and period 2 (6 of 91 women, 6.6%) (p = 0.00034). The percentage of vascular ligation and uterine compression sutures used, also decreased significantly in period 2 (16.2% vascular ligation for period 1 vs. 4.4% for period 2, p = 0.0108; and 9.5% vs. 1.1% uterine compression sutures, p = 0.023). The percentages of embolization and hysterectomy decreased nonsignificantly: 9.5% vs. 2.2%, p = 0.079; and 6.8% vs. 1.1%, p = 0.091, respectively.
Balloon tamponade was used in 38/91 (41.8%) women during period 2, three (7.9%) of whom required subsequent embolization (two patients) and hysterectomy (one in a setting of scheduled cesarean section because of placenta previa accreta). The success rate of tamponade was therefore 92.1% (35/38).
In women treated by balloon tamponade, the mean interval between the start of sulprostone treatment and balloon placement was 52 min (range: 5 min to 5 h 5 min). The balloon was inflated to a mean volume of 400 mL (range: 100-600 mL) and was left in place for a mean duration of 23 h 13 min (range: 11 h 30 min to 41 h 10 min). There was one balloon placement failure.
Details of the comparison of post-delivery features and maternal complications are given in Table 3 .
Discussion
We specifically report here for the first time a significant increase of second-line treatment after the introduction of We noted high assumed failure rates for sulprostone in the two study periods (29.7 and 45.1%). An older study reported an 89% success rate with sulprostone (18) , but our use of sulprostone was less frequent than in the literature and so might be associated with more serious cases, hence our higher failure rate. As an example, Laas et al. (17) reported use of sulprostone in 2.4-3.2% cases, compared with 1.03 and 1.37% in our study. Our findings are in agreement with the 1.38% use of sulprostone in 106 French maternity units reported by Schmitz et al. (19) , who noted a success rate of 83.4% in the absence of tamponade.
The very high success rates of tamponade for the treatment of PPH combined with its ease of use raise the question of the timing of use of this technique. In the future, two other ways to use tamponade should be evaluated: (i) placement of the balloon at the time of sulprostone administration; (ii) replacement of sulprostone by balloon insertion.
Since we introduced balloon tamponade in our obstetrics unit, there has been a significant decrease in the use of embolization or surgery for the treatment of PPH. This finding is comparable to the results of Laas et al. (17) , who also compared two periods in their retrospective study over a five-year period: before and after the introduction of balloon tamponade in PPH management protocols. Unlike us, Laas et al. did not use balloon tamponade in the case of placenta accreta. They found a significant decrease in the use of embolization (8.2 vs. 2.3%, p = 0.006) and conservative surgical management (5.1 vs. 1.4%, p = 0.029) in women who delivered vaginally, but not in women who underwent cesarean section, and a significant decrease in the use of more invasive treatment (13.4 vs. 4.1%, p = 0.001). Laas et al. noted no significant difference between the two periods in the use of hysterectomy or of transfusion. In our study, only one hysterectomy (1.1% of the cases) was performed during period 2, whereas five (6.8%) were performed during period 1. The difference was not statistically significant, no doubt because of an insufficient sample size.
Our success rate with balloon tamponade (92.1%) was similar to that of other studies. The first studies in small series of women reported high success rates of between 60 and 100% (6, 12, 15, 17, (20) (21) (22) (23) .
We found no maternal complications associated with balloon tamponade, and the complication rate was comparable in the two study periods. This study, however, was underpowered to assess these endpoints clearly. Literature reports of complications include two cases of migration of the Bakri balloon through a uterine rupture (24, 25) , in which PPH occurred several days after delivery and required aspiration before balloon placement. We do not know whether in these two cases the rupture was directly associated with balloon tamponade, as both women needed cervical dilation and aspiration beforehand. Nor do we know the long-term rate of complications for the women who required balloon tamponade. In terms of obstetrical and gynecological outcome, pregnancy is possible after Bakri balloon tamponade (26) .
Our study, although retrospective, suggests that balloon tamponade is highly effective. Our results also uphold the assumption that balloon tamponade is easier to implement than interventional radiology and surgery, which cannot therefore be compared outside of a controlled trial, which the literature currently lacks. Although the efficacy of tamponade should be viewed in the light of its widespread use, our findings show that tamponade significantly reduces the need for more invasive treatment of PPH.
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